Price History

Hover for the daily close. The dotted line marks the period open.

Compare PRLD with… →

PRLD Key Statistics

As of Sep 4, 2026

Trading

Open: $5.19
Previous Close: $5.25
Day's Range: 5.19–5.52
52-Week Range: 0.98–6.83
Volume: 400.30K
Beta: 0.96

Valuation

Market Cap: $435.73M
P/E Ratio: unprofitable
P/S ratio: 19.43
EPS (ttm): −0.76

Financials (FY)

Revenue (FY): $12.14M+73.43%
Net Income (FY): −$99.50M
Profit margin: −269.75%
Shares Outstanding: 65.08M
1-Year Return: +378.95%

Dividend and dates

Earnings Date: November 11, 2026estimated
Avg Volume: 493.63K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PRLD Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+173.09%−82.60%−51.49%−29.30%−70.14%+127.45%+88.28%

2020*202120222023202420252026*

Year	Return
2026 (partial year)	+88.28%
2025	+127.45%
2024	−70.14%
2023	−29.30%
2022	−51.49%
2021	−82.60%
2020 (partial year)	+173.09%

As of September 4, 2026.

PRLD Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$12.14M	−$99.50M	−819.6%
2024	$7.00M	−$127.17M	−1816.8%
2023	$0.00	−$121.83M	—
2022	$0.00	−$115.44M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$12.14M	—	−$104.57M	−$99.50M	−819.6%
2024	$7.00M	—	−$139.71M	−$127.17M	−1816.8%
2023	$0.00	—	−$132.28M	−$121.83M	—
2022	$0.00	—	−$123.54M	−$115.44M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PRLD Valuation vs Biotechnology Median

Median of 656 stocks

Metric	PRLD	Biotechnology median	vs median
P/S ratio	19.43	15.26	27% above
Profit margin	−269.75%	0.00%	269.7 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Prelude Therapeutics Incorporated (PRLD) is capitalised at $435.73M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 79.

PRLD last closed at $5.46 on September 4, 2026. That is +$0.21 (+4.00%) against the previous close. Over the past 52 weeks the price has ranged from $0.98 to $6.83. The latest close sits 456.57% above that 52-week low.

Financial Health

In fiscal 2025, Prelude Therapeutics Incorporated reported revenue of $12.14M. Against the prior fiscal year total of $7.00M, that is a change of +73.43%. The same year closed with a net loss of $99.50M. Profit margin runs at −269.75%. That is 269.7 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −0.76.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $12.14M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 19.43. On price-to-sales that is 27.31% above the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +378.95%. Across 5 years the annualized return works out at −31.94%. The reported beta is 0.96. Annualized volatility over the trailing 5 years is 125.74%.

Growth & Income

The record shows no dividend for PRLD.

The strongest complete calendar year on file is 2025 at +127.45%; the weakest is 2021 at −82.60%. Of the 5 complete calendar years on file, 1 finished higher. 2026 is still running; the price is +88.28% year to date.

Peer Comparison

Prelude Therapeutics Incorporated (PRLD) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Prelude Therapeutics Incorporated	PRLD	$435.73M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Prelude Therapeutics Incorporated has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Prelude Therapeutics Incorporated

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Visit website →

Prelude Therapeutics Incorporated (PRLD) Stock Analysis